Otsuka v. Sun Pharma: Tolvaptan Patent Dispute Dismissed Without Prejudice in Landmark Case
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Otsuka Pharmaceutical Co., Ltd. v. Sun Pharmaceutical Industries, Inc. |
| Case Number | 1:24-cv-00740 |
| Court | U.S. District Court for the District of Delaware |
| Duration | June 21, 2024 – January 9, 2026 567 Days |
| Outcome | Stipulated Dismissal — Without Prejudice |
| Patents at Issue | |
| Accused Products | Generic Tolvaptan Tablets (15, 30, 45, 60, 90 mg) |
Case Overview
The Parties
⚖️ Plaintiff
Tokyo-headquartered global pharmaceutical innovator with deep investments in central nervous system and nephrology therapeutics. JYNARQUE® (tolvaptan) represents a significant commercial asset within its nephrology portfolio.
🛡️ Defendant
U.S. subsidiary of Sun Pharma, one of the world’s largest specialty generic pharmaceutical manufacturers. Sun’s filing of an Abbreviated New Drug Application (ANDA) for a generic tolvaptan tablet positioned it as a challenger to Otsuka’s market exclusivity.
Patents at Issue
This landmark case involved three patents protecting tolvaptan formulations and methods of use, the active ingredient in JYNARQUE® tablets. Patents are registered with the U.S. Patent and Trademark Office (USPTO) and are central to pharmaceutical market exclusivity under the Hatch-Waxman Act.
- • US 10,905,694 B2 — Covering formulation or therapeutic use innovations related to tolvaptan
- • US 8,273,735 B2 — An earlier patent in the tolvaptan portfolio, likely covering compound or composition claims
- • US 8,501,730 B2 — A continuation or related application covering additional tolvaptan claims
Developing a similar pharmaceutical product?
Check if your formulation or method of use might infringe these or related patents.
The Verdict & Legal Analysis
Outcome
The case was dismissed without prejudice by joint stipulation on January 9, 2026, after approximately 567 days of litigation. All claims, counterclaims, and affirmative defenses were terminated simultaneously. Critically, “without prejudice” means Otsuka retains the legal right to re-file infringement claims against Sun on these same patents should future circumstances warrant. No damages were awarded, and no injunctive relief was imposed. The specific commercial terms, if any, underlying the dismissal were not publicly disclosed.
Key Legal Issues
The case was predicated on a classic Hatch-Waxman infringement action under 35 U.S.C. § 271(e)(2), triggered by Sun’s ANDA filing. Without prejudice dismissals in this context most commonly reflect a confidential licensing or settlement agreement, Sun’s withdrawal or modification of its ANDA, or a strategic decision by Otsuka to prioritize other enforcement channels. The assertion of three structurally layered patents—spanning composition, formulation, and potentially method-of-treatment claims—suggests Otsuka pursued a portfolio assertion strategy rather than relying on any single patent’s strength, maximizing settlement leverage.
Otsuka filed suit on June 21, 2024, in the U.S. District Court for the District of Delaware — the dominant venue for Hatch-Waxman pharmaceutical patent litigation. The case was assigned to Chief Judge Stephanos Bibas, a former University of Pennsylvania law professor and federal appellate advocate known for his intellectually rigorous opinions.
Legal Representation included **Morris, Nichols, Arsht & Tunnell LLP** for Otsuka, with **Jack B. Blumenfeld** and **Jeremy A. Tigan**. Sun was represented by **Kratz & Barry LLP**, with a five-attorney team including **Timothy H. Kratz**, **George J. Barry III**, **John Thallemer**, **Michael P. Hogan**, and **R. Touhey Myer**.
Freedom to Operate (FTO) Analysis for Tolvaptan
This case highlights critical IP risks in the vasopressin receptor antagonist space. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all 3 related patents in this technology space
- See which companies are most active in tolvaptan patents
- Understand claim construction patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Tolvaptan formulations & methods of use
3 Patents at Issue
In tolvaptan technology space
Strategic Dismissal
Patents remain valid and enforceable
✅ Key Takeaways
Without-prejudice dismissals preserve re-filing rights and avoid adverse claim construction precedent — a strategic tool in multi-patent portfolio litigation.
Search related case law →Delaware’s Hatch-Waxman docket, including cases before Chief Judge Bibas, remains the premier venue for pharmaceutical patent disputes.
Explore precedents →Three-patent assertion strategies increase settlement leverage by multiplying invalidity defense burden.
Analyze litigation strategies →Frequently Asked Questions
Three U.S. patents: US10,905,694 B2, US8,273,735 B2, and US8,501,730 B2 — all related to tolvaptan, the active ingredient in JYNARQUE® tablets.
Both parties jointly stipulated to dismissal under FRCP Rule 41(a)(1)(A)(ii). The underlying commercial terms were not publicly disclosed, though such outcomes in Hatch-Waxman litigation frequently reflect licensing or settlement agreements.
The dismissal without prejudice does not confirm Sun’s right to market generic tolvaptan. Consult FDA’s Orange Book for current patent exclusivity and authorized generic status updates.
“Without prejudice” means Otsuka retains the legal right to re-file infringement claims against Sun on these same patents if future circumstances warrant. It creates no binding precedent on claim construction, validity, or infringement for any of the three asserted patents.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- United States District Court for the District of Delaware — Case 1:24-cv-00740 (via PACER)
- U.S. Patent and Trademark Office — Patent Full-Text Database (for US 10,905,694 B2, etc.)
- FDA Orange Book — Approved Drug Products with Therapeutic Equivalence Evaluations (for JYNARQUE® and tolvaptan)
- Cornell Legal Information Institute — 35 U.S.C. § 271(e)(2) (Hatch-Waxman Act)
- PatSnap — IP Intelligence Solutions for Pharmaceutical Industry
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.